Immunosuppression after liver transplantation

TransplantLinc

Volumn 4, Issue 3, 2002, Pages 63-70

  Girgrah, N ^b   Cattral, M ^b   Lilly, L ^b   Levy, G A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

Drug toxicity; Immunosuppressive agents; Liver transplantation; Therapeutic drug monitoring

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECEPTOR BLOCKING AGENT; TACROLIMUS;

ALOPECIA; ANEMIA; ARTERY THROMBOSIS; ARTICLE; BRADYCARDIA; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DIARRHEA; DRUG MONITORING; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; GRAFT REJECTION; HAIR LOSS; HEADACHE; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTESTINE INJURY; KIDNEY FAILURE; LEUKOPENIA; LIVER DISEASE; LIVER TRANSPLANTATION; MALIGNANT NEOPLASTIC DISEASE; QUALITY OF LIFE; SURVIVAL TIME; THROMBOCYTOPENIA; TREMOR; VIRUS HEPATITIS;

EID: 0036951805     PISSN: 14390027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64 (12): 1755-60
2. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R, Wang W. A randomized bouble blind comparative study of mycophenolate mofetil (MMF) and azathioprine (AZA) in combination with cyclosporine and corticosteroids in liver transplant recipients. Liver Transpl 2001; 7 (5): 442-50
3. Papatheodoridis GV, O'Beirne J, Mistry P, Davidson B, Rolles K, Burroughs AK. Mycophenolate mofetil monotherapy in stable liver transplant patients with cyclosporine-induced renal impairment: a preliminary report. Transplantation 1999; 67 (8): 155-7
4. Borel JF, Baumann G, Chapman I, Donatsch P, Fahr A, Mueller EA, Vigouret JM. In vivo pharmacological effects of ciclosporin and some analogues. Advances in Pharmacology 1996; 35: 115-246
5. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-1115
6. Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, Hendricks L, Guilbault N, Levy G. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 1999; 67 (8): 1133-7
7. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, Touraine JL, Claesson K, Campistol JM, Durand D, Wramner L, Brattstrom C, Charpentier B. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67 (7): 1036-42
8. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimustacrolimus combination immunosuppression. Lancet 2000; 376-7
9. Vincenti F, Kirman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-65
10. Nashan B, Moor R, Amlot P, Schmidt A-G, Abeywickrama K, Soulillou J-P. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. The Lancet 1997; 350:1193-1198
11. Chiba K, Yanagawa Y, Kataoka H, Kawaguchi T, Ohtsuki M, Hoshino Y. FTY 720 a novel immunosuppressant induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. Trans Proc 1999; 31 (1-2): 1230-3
12. Abbasoglu O, Levy MF, Testa G, Jeyarajah DR, Goldstein RM, Husberg BS et al. Ten years of liver transplantation: An evolving understanding of late graft loss. Transplantation 1997; 64: 1801-1807
13. Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, Greig PD, Lilly LB, Heathcote JE, Levy GA, Cattral MS. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32: 87-90
14. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: Meta-analyses of randomized trials. Br Med J 1999; 318: 1104-1107
15. Charco R, Cantarell C, Vargas V, Capdevila L, Lazaro JL, Hidalgo E et al. Serum cholesterol changes in long-term survivors of liver transplantation: A comparison between cyclosporine and tacrolimus therapy. Liver Transpl Surg 1999; 5: 204-208
16. Feray C, Samuel D, Thiers V, Gigou M, Pichon F, Bismuth A, Reynes M, Maisonneuve P, Bismuth H, Brechot C. Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest 1992; 89 (4): 1361-5
17. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 4 (5): S107-S114
18. Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl Surg 1999; 5 (5): 375-80